(Q28287250)

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Beyond LDL cholesterol reduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The forgotten majority: unfinished business in cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Triglycerides and risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Hypertriglyceridemia and cardiovascular risk reduction.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

HDL metabolism in hypertriglyceridemic states: an overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Safety considerations with fibrate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021